NCT07302009 Targeted Temperature Management Via Bladder Monitoring in ICH

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 318 participants in total. It began in 2026-03-15 with a primary completion date of 2027-12-30.

Brief Summary

The goal of this clinical trial is to learn whether a bladder temperature monitoring-guided targeted temperature management (TTM) strategy improves functional recovery in patients with severe intracerebral hemorrhage, compared to conventional temperature monitoring. It will also assess the safety of this monitoring approach. The main questions it aims to answer are: * Does continuous bladder temperature monitoring-guided TTM improve the likelihood of a favorable functional outcome (modified Rankin Scale score 0-2) at 180 days after onset? * What medical problems (such as infections, shivering, deep vein thrombosis, or sepsis) do participants experience while under the TTM strategy? Researchers will compare the intervention group (using continuous bladder temperature monitoring) with the control group (using conventional intermittent temperature monitoring with a mercury thermometer at the armpit) to see if the bladder temperature-guided TTM strategy leads to better outcomes. Participants will: * Be randomly assigned to one of the two temperature monitoring strategies * Receive standard medical and surgical care for severe intracerebral hemorrhage

Eligibility Criteria

Inclusion Criteria: 1. Neurocritical care patients: Study subjects are patients with first-time spontaneous intracerebral hemorrhage. 2. Age ≥ 18 years and ≤ 85 years. 3. Glasgow Coma Scale (GCS) score ≤ 8 at ICU admission. 4. For supratentorial ICH: Hematoma volume \< 60 mL. For subarachnoid hemorrhage (SAH): Modified Fisher grade ≥ 2, and the aneurysm has been treated with endovascular intervention. 5. Pre-morbid modified Rankin Scale (mRS) score of 0 or 1. 6. Signed informed consent provided by a legally authorized representative. Exclusion Criteria: 1. Fever (≥38.0°C) that lasted over 1 hour or occurred more than once prior to enrollment. 2. Pre-existing neurological, psychiatric, or other comorbidities that may compromise the assessment of neurological or functional outcomes. 3. Underlying conditions with a life expectancy of less than 6 months, estimated prior to onset. 4. Severe injury indicative of poor prognosis: brain death, receiving palliative care only, or irreversible brain injury. 5. Pregnancy. 6. Unilateral or bilateral pupillary dilation. 7. Currently participating in other investigational/interventional clinical trials (involving medical devices or drugs). 8. Subjects deemed ineligible for enrollment by the investigator.

Contact & Investigator

Frequently Asked Questions

Related Trials